Publications by authors named "Peter Lloyd"

Claim this Profile
A
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.
Johann S de Bono, Anja Williams, Ignacio Melero, Anuradha Jayaram, Jessica E Hawley, Peter Lloyd

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic Fluid-Driven Vine Robots for Minimally Invasive Tissue Biopsy Sampling.
Joshua Davy, Thomas P Dean, Nikita J Greenidge, Benjamin Calmé, Peter Lloyd

Adv Intell Syst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Safety, Efficiency, Cost, and Satisfaction Across a Musculoskeletal Pathway Using the Digital Assessment Routing Tool for Triage: Quality Improvement Study.
Cabella Lowe, Laura Atherton, Peter Lloyd, Anna Waters, Dylan Morrissey

J Med Internet Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan Martín-Liberal, Peter Lloyd

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community groups, organisations, and employers respond to the challenges of the Covid-19 pandemic: A story of resilience and continued vulnerability.
Katharine Abba, Adele Ring, Peter Lloyd, Rachel Anderson de Cuevas, Shaima Hassan

BMC Public Health· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan Martín-Liberal, Peter Lloyd

Nature· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'Blue-lighting' seizure-related needs in care homes: a retrospective analysis of ambulance call-outs for seizures in North West England (2014-2021), their management and costs, with community comparisons.
Adam J Noble, Steven Lane, Peter Lloyd, Beth Morris, Steve Bell

BMJ Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"In the wilderness…dealing with difficult situations": Knowledge exchange with care home staff in England on managing seizures and epilepsy - An initial exploration.
Beth Morris, Louise Roper, Peter Lloyd, Tom Shillito, Pete Dixon

Epilepsy Behav· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future cardiovascular healthcare via magnetic resonance imaging-driven robotics.
Peter Lloyd, Erica Dall'Armellina, Jurgen E Schneider, Pietro Valdastri

Eur Heart J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Specific Magnetic Catheters for Atraumatic Autonomous Endoscopy.
Giovanni Pittiglio, Peter Lloyd, Tomas da Veiga, Onaizah Onaizah, Cecilia Pompili

Soft Robot· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization and fabrication of programmable domains for soft magnetic robots: A review.
Alistair Bacchetti, Peter Lloyd, Silvia Taccola, Evan Fakhoury, Sandy Cochran

Front Robot AI· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Rosemina Merchant, Carole Galligan, Manjunatha Ankathatti Munegowda, L Bruce Pearce, Peter Lloyd

J Immunother Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary Inverse Material Identification: Bespoke Characterization of Soft Materials Using a Metaheuristic Algorithm.
Michele Di Lecce, Onaizah Onaizah, Peter Lloyd, James H Chandler, Pietro Valdastri

Front Robot AI· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Fiber Reinforcement Within Magnetically Actuated Soft Continuum Robots.
Peter Lloyd, Zaneta Koszowska, Michele Di Lecce, Onaizah Onaizah, James H Chandler

Front Robot AI· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques.
Paul E Harris, Trevor Brasel, Christopher Massey, C V Herst, Scott Burkholz, Peter Lloyd

Vaccines (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling the Spread of the Coronavirus: A View from Economics.
Peter Lloyd, Robert Dixon

Aust Econ Rev· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymer, Additives, and Processing Effects on N95 Filter Performance.
Gregory S Larsen, Yongqiang Cheng, Luke L Daemen, Tej N Lamichhane, Dale K Hensley, Peter Lloyd

ACS Appl Polym Mater· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H Sodergren, Bristi Basu, Peter Lloyd

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling Consciousness within Mental Monism: An Automata-Theoretic Approach.
Peter B Lloyd

Entropy (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4.
Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, Peter Lloyd

MAbs· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Pitch Discrimination Screening Test for Preschool Children.
Maria Kulick Abramson, Peter J Lloyd

J Am Acad Audiol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody.
Wai Siang Law, Jean-Christophe Genin, Christian Miess, Gwenola Treton, Andrew Paul Warren, Peter Lloyd

Bioanalysis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Zhanna Kobalava, Svetlana Villevalde, Yulia Kotovskaya, Holger Hinrichsen, Marc Petersen-Sylla, Peter Lloyd

Br J Clin Pharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
Marion Dahlke, Dik Ng, Masayuki Yamaguchi, Surendra Machineni, Sergej Berger, Peter Lloyd

J Clin Pharmacol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs.
Soichiro Matsushima, Yue Huang, Hikoe Suzuki, Junichi Nishino, Peter Lloyd

Expert Opin Drug Metab Toxicol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis